Latest News | Glenmark Pharmaceuticals Acquires Certain OTC Drugs from Wockhardt in US

New Delhi, Jun 28 (PTI) Glenmark Pharmaceuticals Ltd on Tuesday said it has acquired the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd in the US.

The acquisition by the company's fully-owned subsidiary Glenmark Pharmaceuticals Inc, USA includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets, 10 mg and 20 mg used to treat and prevent ulcers in the stomach and intestine, the company said in a statement.

Also Read | Motorola Moto G42 India Launch Tipped for July 4, 2022.

The company, however, did not disclose the financial details.

Glenmark has also acquired ANDAs of anti-allergy medicine cetirizine hydrochloride tablets, 5 mg and 10 mg, indigestion, heartburn and acid reflux treatment drug Lansoprazole delayed-release capsules USP, 15 mg and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent indicated for allergic conjunctivitis and allergic rhinitis, in the US.

Also Read | Google To Shut Down Hangouts in November 2022, Tells Users To Switch To Chat.

"The over-the-counter market has long been an important segment of Glenmark's portfolio around the world. Our acquisition of these ANDAs represents the continued expansion of our business into the OTC market here in the United States and our commitment to ensuring patients have access to high quality, affordable medicines," Glenmark Pharmaceuticals Inc, USA, President Sanjeev Krishan said.

Glenmark said its current portfolio consists of 175 products authorised for distribution in the US market and 48 ANDAs pending approval with the USFDA.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)